Ginsenoside-Rg1, the most prevalent active constituent of Panax ginseng, has been shown to possess potent proangiogenic properties and therefore poses special interest for the development as a novel modality for angiotherapy. Rg1 can activate the glucocorticoid receptor (GR). However, the mechanism that transmits these pro-angiogenic effects is still unclear.
Introduction
Angiogenesis, the formation of new vessels from existing ones, is a key step in many physiological events. It also plays an important role in pathological conditions, such as chronic wound and ischaemic diseases, and its manipulation is an important therapeutic target. 1 Glucocorticoids have been used in therapeutic angiogenesis owing to their ability to regulate angiogenesis in vitro and in vivo. 2 Glucocorticoids classically exert their effects by binding to the glucocorticoid receptor (GR), a member of the nuclear receptor superfamily, to modulate gene transcription. However, it is increasingly clear that the widespread effect of glucocorticoids on gene expression (approximately 1% of the genome is being affected) 3 leads to undesirable side effects including hypertension, bone loss, skin bruising, and increased susceptibility to infection, which severely limit their therapeutic effectiveness. Panax ginseng C.A. Meyer is a well-known traditional Chinese medicine that has been used extensively for thousands of years. It is now one of the most popular alternative medicines consumed in large amounts worldwide and appears in the pharmacopoeias of many countries, including the USA and Europe, for its purported beneficial effects in the central nervous, cardiovascular, endocrine, and immune systems. 4 In the USA alone, the annual retail sale reaches US $120 million and the global market is more than US$19.5 billion. Ginsenosides, which are steroidal saponins, are the principal pharmacologically active components of ginseng. To date, more † These authors contributed equally to this work. than 30 different ginsenosides have been identified, in which Rg1 is among the most abundant and active ingredients. 5 In an earlier work, Rg1 was demonstrated to be a highly stable pro-angiogenic compound by upregulating in vitro proliferation, migration, chemoinvasion, and tube formation in human umbilical vein endothelial cells (HUVECs) as well as ex vivo aortic sprouting and in vivo neovascularization. 6 Rg1 has been shown to be a functional ligand of GR. 7, 8 Intriguingly, the angiogenic effect of Rg1 is mediated through a rapid activation of phosphatidylinositol 3-kinase (PI3K)/Akt after binding to the GR, suggesting the involvement of an unconventional, nongenomic signalling. 6, 8, 9 This is of particular interest, as it is increasingly evident from the literature that a non-genomic action may be more beneficial in clinical use, with similar clinical efficacy but fewer side effects, than the genomic mechanism. 10 However, despite the obvious importance of non-genomic effects of GR, the precise underlying mechanism is still largely unknown.
In this study, we report for the first time that Rg1 increases interaction between GR and fibroblast growth factor receptor-1 (FGFR-1) and mediates its ligand-independent transactivation, resulting in PI3K/ Akt/eNOS activation and consequent tubulogenesis. These findings provide an attractive mechanism whereby Rg1 can affect angiogenesis upon GR.
Methods

Reagents
Rg1 (purity .98%) was purchased from Division of Chinese Materia Medica and Natural Products, National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), Ministry of Public Health, China. The stock solution of Rg1 (50 mM) was prepared in sterile DMSO.
Culture medium M199, endothelial cell growth supplement (ECGS), and GR antagonist RU486 were purchased from Sigma (St Louis, MO, USA). The inhibitors genistein, AG1024, K252a, SU1498, and SU5402, were bought from Calbiochem (San Diego, CA, USA). FGFR-1 siRNA (5 ′ -GCCACACUCUGCACCGCUA-3 ′ ) and non-targeting siRNA duplex (#D-001810-0X) were obtained from Dharmacon (Lafayette, CO, USA). Phospho-Akt (Ser-473), total Akt, phospho-eNOS (Ser-1177), total eNOS, and FGFR-1 antibodies were purchased from Cell Signaling (Beverly, MA, USA). GR antibody was from Santa Cruz (Santa Cruz, CA, USA). Furthermore, b-actin antibody was obtained from Sigma and anti-phosphotyrosine was from Upstate Biotechnology (Lake Placid, NY, USA).
Cell culture and treatments
HUVECs were obtained from Clonetics (San Diego, CA, USA) and cultured in medium 199 supplemented with 20% FBS, 20 mg/mL ECGS, 90 U/mL heparin, and 1% penicillin -streptomycin in a humidified incubator at 378C with 5% CO 2 . HUVEC between passages 2 and 8 were used in these studies to ensure genetic stability of the culture.
For inhibitor studies, cells were pre-treated with RU486 (10 mM), genistein (50 mM), AG1024 (2 mM), K252a (50 nM), SU1498 (40 mM), or SU5402 (20 mM) for 30 min at 378C before Rg1 (150 nM) stimulation. Cells transfected with the FGFR-1 siRNA or non-targeting siRNA as nonspecific control were incubated for 24 h prior to Rg1 stimulation. Transfection was performed using siLentFect (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions.
Confocal microscopy
Cover slips were fixed in 4% paraformaldehyde, permeabilized with 0.05% Triton X-100, washed in PBS, and blocked with 5% bovine serum albumin in PBS. The cover slips were incubated with anti-GR (1:500) or anti-FGFR-1 (1:500) at room temperature for 1 h. After washing with PBS, cover slips were incubated with AlexaFluor568 (1:5000) or AlexaFluor488 (1:5000) (Invitrogen) secondary antibodies for 1 h. For negative controls, cells were treated with non-specific rabbit IgG instead of primary antibody. The cells were washed again in PBS, mounted in aqueous antifade medium (Vector Laboratories) followed by analysis using a Zeiss LSM-510 multi-tracking laser-scanning confocal microscope (Frankfurt, Germany).
Western blotting and immunoprecipitation
The cells were lysed in RIPA buffer [150 mM NaCl, 50 mM Tris (pH 7.4), 2 mM EDTA, 0.2% SDS, 1% Triton X-100] supplemented with protease and phosphatase inhibitor cocktail. Fifty micrograms of protein were separated by SDS -polyacrylamide gels, transferred to nitrocellulose membranes, probed with phospho-Akt (1:1000) and phospho-eNOS (1:1000) overnight at 48C, and developed with chemiluminescence (Amersham). The blots were stripped and reprobed for total Akt (1:1000), eNOS (1:1000), and b-actin (1:2000). Immunoprecipitations were carried out by incubation of 750 mg lysate with anti-FGFR-1 (1:50) in the presence of 1:1 Protein A/G agarose (Santa Cruz) at 48C overnight with constant agitation followed by three washes in solubilization buffer and extraction of beads in 30 mL sample buffer at 958C for 5 min. Normal IgG was performed in parallel as a negative control.
Reverse transcription -PCR
Total RNA was isolated using TRIzol reagent and cDNA was synthesized using SuperScript Reverse Transcriptase (Invitrogen). cDNA (300 ng) was amplified by PCR. The primers for FGF-1 were sense 5 ′ -CACAT TCAGCTGCAGCTCAG-3 ′ and antisense 5 ′ -TGCTTTCTGGCCATAG TGAGTC-3 ′ , and the primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were sense 5 ′ -CGGAGTCAACGGATTTGGTCG TAT-3 ′ and antisense 5 ′ -AGCCTTCTCCATGGTGGTGAAGAC-3 ′ . The cycling conditions for both FGF-1 and GAPDH were as follows: initial denaturation at 958C for 3 min followed by 30 cycles of denaturation at 958C for 30 s, annealing at 558C for 30 s, and extension at 728C for 30 s. The PCR products were subjected to gel electrophoresis, visualized by ethidium bromide, and quantified using a bio-imaging analyzer (Bio-Rad).
Tube formation assay
HUVECs were seeded on Matrigel-coated 24-well plate (BD Biosciences, San Jose, CA, USA) at 1×10 5 cells/well. The cells were untreated or treated with Rg1 or with a combination of Rg1 and various small molecule inhibitors or FGFR-1 siRNA for 6 h at 378C. Images were captured using a phase contrast microscope (×10) using a CCD camera. Four microscopic fields were randomly selected for each well without overlap, and the number of tube-like structures per field was counted.
Statistical analysis
All experiments were repeated at least three times, and data were presented as the mean+ SD. Statistical analysis was carried out using ANOVA followed by Tukey's post hoc test (GraphPad Software, San Diego, CA, USA). P , 0.05 was considered significant.
Results
Role of FGFR-1 in GR-dependent activation of PI3K/Akt
As GR lacks enzymatic activity, its ability to induce PI3K/Akt activity may depend on its association with other signalling systems. The receptor tyrosine kinases (RTKs) are a set of enzymes that can activate a number of signalling effectors such as PI3K, and several RTKs, including insulin-like growth factor receptor, hepatocyte growth factor receptor (c-Met), vascular endothelial growth factor receptor (VEGFR), and FGFR-1, have been implicated in angiogenesis. 11 Thus, in search for a mechanism underlying PI3K/Akt activation by GR, we examined whether RTKs could be involved. Using a set of inhibitors that specifically inhibit various RTKs of interest, including genistein (general RTKs), AG1024 (IGF-1R), K252a (c-Met), SU1498 (VEGFR), and SU5402 (FGFR-1), we found that only pre-incubation of HUVECs with the general RTK inhibitor genistein and the FGFR-1 inhibitor SU5402 completely abolished the enhancement of Akt activity following Rg1 stimulation ( Figure 1A) . Furthermore, we also investigated the phosphorylation status of eNOS, a downstream target of Akt, and, importantly, a key signalling molecule and regulator in angiogenesis. 12 As shown in Figure 1B , Rg1 induced a rapid phosphorylation of eNOS in HUVEC, which could be inhibited by SU5402. As an alternative approach, we used siRNA. FGFR-1 siRNA also inhibited the activation of Akt and subsequent eNOS phosphorylation, confirming that the effect was FGFR-1 specific ( Figure 2) . As a negative control, non-specific siRNA did not show any inhibitory effects ( Figure 2) . Activation of FGFR-1 implies a rapid stimulation of its intrinsic kinase activity resulting in increased phosphorylation of tyrosine residues at its intracellular domain. Thus, to further investigate the involvement of FGFR-1 in signalling downstream of GR, the accumulation of hyperphosphorylated, active forms of FGFR-1 was monitored on FGFR-1 immunoprecipitates. By using this approach, we found that phosphorylated tyrosine levels in FGFR-1 were elevated upon Rg1 stimulation. The activation of FGFR-1 was rapid, which was noted at 5 min, became more evident afterward, and peaked at 15 min after Rg1 stimulation ( Figure 3A ).
Activation of FGFR-1 by Rg1-mediated GR is ligand-independent
Conceivably, HUVECs may produce soluble ligands, such as FGF-1, 13 which could bind to the extracellular ligand binding domain of FGFR-1 and activate the receptor. However, Rg1 had no effect on FGF-1 mRNA levels ( Figure 3B) . Moreover, the FGFR-1 neutralizing antibody we used to block the extracellular ligand binding domain of FGFR-1 was ineffective in suppressing the activation of Akt upon Rg1 stimulation (data not shown). The activation of FGFR-1 stimulated by Rg1 was prevented by RU486 ( Figure 3C) . Therefore, our data suggest that the activation of Akt by Rg1-mediated GR activation is achieved through a ligand-independent activation of FGFR-1.
GR and FGFR-1 form a complex upon Rg1 stimulation
In light of the involvement of FGFR-1 in GR-mediated activation of PI3K/Akt, we decided to investigate the molecular basis of their interaction. As an approach, we examined whether GR and FGFR-1 can physically associate with each other. As shown in Figure 4A , FGFR-1 was effectively coimmunoprecipitated with GR. The amount of FGFR-1 coimmunoprecipitating with GR increased upon Rg1 stimulation, and reprobing the same blots with antibody directed against FGFR-1 confirmed that the induction of complex formation was not owing to differences in immunoprecipitated FGFR-1. No coimmunoprecipitated GR was detected when using IgG as a control.
These findings suggest a physical interaction between GR and FGFR-1 and prompt us to further investigate their functional relationship by immunofluorescence experiments. As illustrated in Figure 4B , in untreated cells, it was possible to detect a basal level of FGFR-1 associated with GR, as suggested by the overlapping distribution of FGFR-1 with that of GR. Interestingly, upon stimulation with Rg1, GR was mainly detected in the cell periphery, and increased FGFR-1 and GR colocalization was observed. Together, these experiments point to a co-clustering of GR with FGFR-1 in HUVECs, which leads to the activation of PI3K/Akt and the consequent stimulation of eNOS.
FGFR-1 signalling promotes angiogenesis by Rg1
To determine the physiological significance of this pathway in the angiogenic phenotype of Rg1, tube formation assay was performed. This assay is the most simple and classical angiogenesis assay in vitro and has been described as representing the multi-step process of angiogenesis involving cell adhesion, migration, and differentiation. 14 Figure 5A , HUVECs aligned and formed tube-like network structures in the presence of Rg1. Both RU486 and SU5402 alone or in combination prevented Rg1-induced increase in tube formation. The effect of SU5402 was specific, as no inhibition was observed using other RTK inhibitors (data not shown). Similarly, transfection with FGFR-1 siRNA revealed a significant decrease in Rg1-induced angiogenic tube formation alone or in the presence of RU486 or SU5402, confirming that the effect was GR-FGFR-1 specific ( Figure 5B) . Together, these data show a critical role of GR/ FGFR-1 activation in the induction of Rg1 pro-angiogenic cellular responses in endothelial cells.
As shown in
Discussion
Rg1 on endothelial cells plays a significant role in the angiogenic properties of ginsenoside. In an effort to elucidate the underlying mechanisms, we and others have previously shown that Rg1 acutely stimulates NO production in endothelium and that this is owing to the activation of GR, leading to PI3K/Akt stimulation. 6, 8 In the present study, we have demonstrated that GR is coupled to FGFR-1 as a mechanism for the non-nuclear role of GR in endothelial cells. To our knowledge, this is also the first evidence that in any cell type GR interacts with RTKs. Classically, activation of GR results in direct binding of the receptor to glucocorticoid response element sequences in target genes, leading to initiation or repression of transcription. However, there is now increasing evidence that GR can exert specific, non-genomic actions. For example, there exist very rapid GR effects on the brain and cardiovascular systems which could not be blocked by a transcription inhibitor, making transcriptional mechanisms of action unlikely. 15, 16 The crosstalk of GR with FGFR-1 represents a physiologically important signalling pathway by which Rg1 regulates angiogenesis. As FGFR-1 also has vasodilatory, anti-thrombotic, and anti-inflammatory properties, 17 -19 the beneficial effects of Rg1 may extend beyond its angiogenic properties. Although most of the GR is localized to the cytoplasm, we found that there is an increased level of membrane GR after Rg1 stimulation. Similarly, membranebound GRs have been identified in lymphoid cell lines 20 and human peripheral blood mononuclear cells, 21 but their functional significance remains unclear.
In search of mechanisms underlying GR regulation of PI3K/Akt, we found that GR transactivated FGFR-1. This provides a novel and attractive mechanism whereby GR, which does not exhibit any enzymatic activity, can lead to PI3K/Akt activation. Our finding is also the first to report activation of RTK by GR. The interaction between GR and FGFR-1 is especially interesting given that FGFR-1 is a potent angiogenic growth factor. 22 There is also accumulating evidence that certain non-genomic actions of oestrogen, progesterone, androgen, and aldosterone involve steroid hormone receptors acting through RTK mechanisms. 23 However, our results show that GR and other steroid hormone receptors have distinct effects on RTK, via distinct mechanisms. Unlike other steroid hormone receptors in most cases, FGFR-1 regulation by GR is ligand independent. Nevertheless, how GR transactivates FGFR-1 is not known, but appears to involve complex formation between GR and FGFR-1. In addition to the effects described here, several other rapid downstream signalling cascades of GR have been reported. For example, glucocorticoids inhibit prostaglandin synthesis and activation of NF-kB by non-GRE-dependent mechanisms. 24 Other reported nongenomic effects include activation of MAPKs 25 and c-src. 26 More recently, we and other laboratories have provided evidence for the activation of PI3K/Akt by GR. 6, 9, 16 However, the underlying mechanism(s) by which GR activates PI3K/Akt has remained unclear. In this study, we present multiple lines of converging evidence that indicates a direct interaction with FGFR-1 mediates GR stimulation of PI3K/Akt. Whereas inhibition with genistein implicates any RTK, attenuation by Colocalization is shown in yellow in the merge images. Micrographs, ×100 magnification.
Rg1 activation of GR/FGFR-1 crosstalk SU5402 narrows it down to FGFR-1. The use of FGFR-1 siRNA confirms the result. The role of FGFR-1 is further supported by the demonstration of an interaction between GR and FGFR-1 proteins from HUVEC that is dependent on Rg1 stimulation. There are several clinical settings in which induction of angiogenesis is desirable. These include hypertension, diabetes, chronic inflammation including arthrosclerosis, wound healing, and tissue regeneration. eNOS is the host factor that is engaged in the pathogenesis of most of these conditions. 27 Thus, a treatment strategy directed at eNOS is likely to be optimal. The present study identified Rg1 as a novel modulator of eNOS phosphorylation. The non-genomic activity of Rg1 also opens up the exciting possibility as a safer alternative with fewer side effects. Indeed, the extract from Sanqi ginseng, which has a predominance of Rg1, is considered the key ingredient for the treatment of trauma injuries and for promoting microcirculation. 28 The dosage (150 nM; 0.12 g/L) utilized in this study is similar to that observed in consuming 0.65-3.65 g of Rg1, based on the oral bioavailability of 3.29-18.4% for Rg1. 29, 30 In summary, the results of this study reveal a new mechanism whereby Rg1 may promote angiogenesis. This mechanism involves GR, which cooperates with FGFR-1, to activate PI3K/Akt/eNOS signalling, ultimately enhancing angiogenesis. These findings also provide new insights into the non-genomic GR-dependent modulation of signal transduction pathways, which might offer the opportunity to target specific pathways that may be manipulated in treating pathological states.
